Plasma sphingolipids in patients with sickle cell disease: Multiple‐site vaso‐occlusive crises could be associated with lower sphingolipid levels

Abstract

AbstractAlthough sickle cell disease (SCD) and its manifestations have been associated with various lipid alterations, there are a few studies exploring the impact of sphingolipids in SCD. In this study, we determined plasma ceramide (Cer) and sphingomyelin (CerPCho) species and investigated their association with the crisis in SCD. SCD patients (N = 27) suffering from vaso‐occlusive crisis (VOC) or acute chest syndrome (ACS) were involved in this study. Blood samples were drawn at crisis and later at steady state periods. Clinical history, white blood cell count (WBC), C‐reactive protein and lactate dehydrogenase (LDH) levels were recorded. 16:0, 18:0, 20:0, 22:0 Cer and 16:0, 18:0, 24:0 CerPCho were measured via LC–MS/MS. All measured Cer and CerPCho levels of SCD patients at crisis and steady‐state were found to be similar. Inflammation‐related parameters were significantly higher in patients with ACS compared to single‐site VOC. Patients with multiple‐site VOC were found to have significantly lower sphingolipid levels compared with those with single‐site VOC, at crisis (16, 18, 24 CerPCho and 18, 22 Cer) and at steady‐state (24:0 CerPCho and 18 Cer). Our results show that sphingolipid levels in SCD patients are similar during crisis and at steady state. However, lower sphingolipid levels appear to be associated with the development of multiple‐site VOC. Since the differences were observed at both crisis and steady‐state, sphingolipid level could be an underlying factor associated with crisis characteristics in patients with SCD.